The pharmaceutical industry is seeing a important shift in blood sugar therapy with the emergence of GLP-1 transdermal devices. These innovative delivery systems offer a potentially easy alternative to needle injections for individuals living with type 2 diabetes. By circumventing the requirement for frequent injections, GLP-1 adhesives promise to